{"component": "clause", "props": {"groups": [{"snippet_links": [{"key": "sole-discretion", "type": "definition", "offset": [89, 104]}, {"key": "subject-to", "type": "definition", "offset": [133, 143]}, {"key": "launch-quantities", "type": "definition", "offset": [163, 180]}, {"key": "pursuant-to-the", "type": "definition", "offset": [197, 212]}, {"key": "section-42", "type": "clause", "offset": [236, 247]}, {"key": "use-commercially-reasonable-efforts", "type": "clause", "offset": [249, 284]}, {"key": "otc-field", "type": "definition", "offset": [312, 321]}, {"key": "in-the-united-states", "type": "clause", "offset": [326, 346]}, {"key": "in-the-territory", "type": "clause", "offset": [403, 419]}, {"key": "sole-and-exclusive-remedy", "type": "clause", "offset": [557, 582]}, {"key": "notice-to", "type": "clause", "offset": [602, 611]}, {"key": "licenses-granted", "type": "clause", "offset": [629, 645]}, {"key": "technical-information", "type": "definition", "offset": [717, 738]}, {"key": "exclusive-licenses", "type": "clause", "offset": [746, 764]}, {"key": "the-restrictions", "type": "clause", "offset": [785, 801]}, {"key": "section-23", "type": "clause", "offset": [821, 832]}, {"key": "within-thirty", "type": "clause", "offset": [874, 887]}, {"key": "days-after", "type": "definition", "offset": [893, 903]}, {"key": "following-the", "type": "definition", "offset": [979, 992]}, {"key": "provided-that", "type": "clause", "offset": [1132, 1145]}, {"key": "other-legal-action", "type": "clause", "offset": [1310, 1328]}, {"key": "right-of", "type": "definition", "offset": [1367, 1375]}, {"key": "third-party", "type": "definition", "offset": [1380, 1391]}, {"key": "promptly-notify", "type": "clause", "offset": [1419, 1434]}, {"key": "in-writing", "type": "definition", "offset": [1441, 1451]}, {"key": "after-receipt-of", "type": "clause", "offset": [1503, 1519]}, {"key": "written-request", "type": "definition", "offset": [1528, 1543]}, {"key": "reasonably-believes", "type": "definition", "offset": [2013, 2032]}], "snippet": "WCH shall not be required to Launch Products in any country unless it determines, in its sole discretion, to do so. If WCH does not, subject to supply by IMPAX of launch quantities of such Product pursuant to the forecasts set forth in Section 4.2, use Commercially Reasonable Efforts to Launch a Product in the OTC Field (i) in the United States within three (3) months, or (ii) in the another country in the Territory within five (5) months, following such Product having FTO Status for the OTC Field in such country, then IMPAX, at its option and as its sole and exclusive remedy, may, upon written notice to WCH, convert the licenses granted hereunder in such country for such Product under the IMPAX Patents and Technical Information to non-exclusive licenses (and thereby remove the restrictions placed on IMPAX in Section 2.3 for such Product in such country) unless within thirty (30) days after such written notice WCH Launches Product in the OTC Field in such country. Following the Launch of a Product in any country of the Territory, WCH shall use Commercially Reasonable Efforts to market such Product in such country; provided that nothing shall require WCH to continue marketing a Product in a country if WCH determines, in its sole judgment, that such Product may be subject to a regulatory or other legal action or infringe any intellectual property right of any Third Party in such country. WCH shall promptly notify IMPAX in writing of such discontinuance. If within thirty (30) days after receipt of IMPAX\u2019s written request, WCH does not resume marketing such Product in such country, then IMPAX, at its option and as its sole and exclusive remedy, may, upon written notice to WCH, convert the licenses granted hereunder in such country for such Product under the IMPAX Patents and Technical Information to non-exclusive licenses (and thereby remove the restrictions placed on IMPAX in Section 2.3 for such Product in such country). If at anytime after Launch of a Product in a country, IMPAX reasonably believes that WCH is not using Commercially Reasonable Efforts to market such Product in such country, then IMPAX shall notify WCH and if WCH does not begin to use Commercially Reasonable Efforts to market such Product within such country within thirty (30) days after such written notice, then IMPAX, at its option and as its sole and exclusive remedy, may, upon written notice to WCH, convert the licenses granted hereunder in such country for such Product under the IMPAX Patents and Technical Information to non-exclusive licenses (and thereby remove the restrictions placed on IMPAX in Section 2.3 for such Product in such country).", "samples": [{"hash": "e1osJmpJ03S", "uri": "/contracts/e1osJmpJ03S#product-launch", "label": "Development, License and Supply Agreement (Impax Laboratories Inc)", "score": 21.0, "published": true}, {"hash": "1H73CZ3Zju8", "uri": "/contracts/1H73CZ3Zju8#product-launch", "label": "Development, License and Supply Agreement (Impax Laboratories Inc)", "score": 21.0, "published": true}], "size": 3, "hash": "90d3e752f6cdf66e492d0cb5493d6234", "id": 5}, {"snippet_links": [{"key": "first-commercial", "type": "definition", "offset": [29, 45]}, {"key": "product-model", "type": "clause", "offset": [96, 109]}, {"key": "third-party", "type": "definition", "offset": [123, 134]}], "snippet": "This means the date on which first commercial-level shipping of the FEELit Mouse Product or any Product Model commences to third party unaffiliated customers of Logitech or a Logitech Affiliate.", "samples": [{"hash": "gJJfPdZg74S", "uri": "/contracts/gJJfPdZg74S#product-launch", "label": "Intellectual Property License Agreement (Immersion Corp)", "score": 18.0, "published": true}, {"hash": "fGRB8vYoyd", "uri": "/contracts/fGRB8vYoyd#product-launch", "label": "Technology Product Development Agreement (Immersion Corp)", "score": 18.0, "published": true}, {"hash": "ctYmEX7msxj", "uri": "/contracts/ctYmEX7msxj#product-launch", "label": "Technology Product Development Agreement (Immersion Corp)", "score": 18.0, "published": true}], "size": 4, "hash": "7a642a0b37a4aba1518925de4e14fa77", "id": 1}, {"snippet_links": [{"key": "development-work", "type": "definition", "offset": [25, 41]}, {"key": "the-non", "type": "clause", "offset": [48, 55]}, {"key": "integrated-product-development-plan", "type": "definition", "offset": [56, 91]}, {"key": "product-launch-date", "type": "definition", "offset": [118, 137]}], "snippet": "It is estimated that the Development Work under the Non-Integrated Product Development Plan will be completed and the Product Launch Date will take place on or before September 30, 2010.", "samples": [{"hash": "g9BpBiPiZiF", "uri": "/contracts/g9BpBiPiZiF#product-launch", "label": "Development, Supply and Distribution Agreement (Cambridge Heart Inc)", "score": 21.1423683167, "published": true}, {"hash": "iqlrOPMiM8h", "uri": "/contracts/iqlrOPMiM8h#product-launch", "label": "Development, Supply and Distribution Agreement (Cambridge Heart Inc)", "score": 21.0, "published": true}, {"hash": "fNiXCp7Ecep", "uri": "/contracts/fNiXCp7Ecep#product-launch", "label": "Development, Supply and Distribution Agreement (Cambridge Heart Inc)", "score": 21.0, "published": true}], "size": 3, "hash": "95a8c7a56aebf0e63c91926f4ad3aef7", "id": 4}, {"snippet_links": [{"key": "without-limiting", "type": "clause", "offset": [0, 16]}, {"key": "general-obligations", "type": "clause", "offset": [21, 40]}, {"key": "section-41", "type": "clause", "offset": [47, 58]}, {"key": "efforts-to-obtain", "type": "clause", "offset": [108, 125]}, {"key": "pricing-approvals", "type": "clause", "offset": [164, 181]}, {"key": "marketing-materials", "type": "clause", "offset": [213, 232]}, {"key": "in-the-territory", "type": "clause", "offset": [263, 279]}, {"key": "governmental-approval", "type": "clause", "offset": [291, 312]}, {"key": "notwithstanding-the-foregoing", "type": "clause", "offset": [392, 421]}], "snippet": "Without limiting its general obligations under Section 4.1, INVENIAI will exert its COMMERCIALLY REASONABLE EFFORTS to obtain, as rapidly as possible, all required pricing approvals and approvals of labelling and marketing materials for a PRODUCT in each country in the TERRITORY in which a GOVERNMENTAL APPROVAL for such PRODUCT has been granted, and to launch such PRODUCT in such country. Notwithstanding the foregoing, DS acknowledges that it may not be commercially reasonable for INVENIAI to seek pricing approvals or launch a PRODUCT in every country.", "samples": [{"hash": "7lcszLEq4nc", "uri": "/contracts/7lcszLEq4nc#product-launch", "label": "License Agreement (Invea Therapeutics, Inc)", "score": 36.9534568787, "published": true}, {"hash": "7RTrKp7ElAt", "uri": "/contracts/7RTrKp7ElAt#product-launch", "label": "License Agreement (Invea Therapeutics, Inc)", "score": 36.1868591309, "published": true}, {"hash": "dzQOj1u3nR9", "uri": "/contracts/dzQOj1u3nR9#product-launch", "label": "License Agreement (Invea Therapeutics, Inc)", "score": 34.5961685181, "published": true}], "size": 3, "hash": "663f8849390d13bad0cfaa67eb90c14e", "id": 2}, {"snippet_links": [{"key": "manufacturing-program", "type": "definition", "offset": [15, 36]}, {"key": "process-development-program", "type": "definition", "offset": [100, 127]}], "snippet": "5 1.34 Product Manufacturing Program . . . . . . . . . . . . . . . . . . . . . . . . 5 1.35 Product Process Development Program . . . . . . . . . . . . . . . . . . . . . 5 1.36", "samples": [{"hash": "bKbVNe5kW6S", "uri": "/contracts/bKbVNe5kW6S#product-launch", "label": "Agreement (Ophidian Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "7zco0EfkoBW", "uri": "/contracts/7zco0EfkoBW#product-launch", "label": "Agreement (Ophidian Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "5LMGgLA0F2E", "uri": "/contracts/5LMGgLA0F2E#product-launch", "label": "Agreement (Ophidian Pharmaceuticals Inc)", "score": 18.0, "published": true}], "size": 3, "hash": "ec9ec081fb3a5ff601f7cde21205aefd", "id": 3}, {"snippet_links": [{"key": "sale-of-product", "type": "clause", "offset": [42, 57]}, {"key": "unrelated-third-party", "type": "definition", "offset": [64, 85]}, {"key": "use-or-consumption", "type": "definition", "offset": [130, 148]}, {"key": "general-public", "type": "clause", "offset": [156, 170]}], "snippet": "The date on which Athenex makes its first sale of Product to an unrelated third party in an arm\u2019s length transaction for ultimate use or consumption by the general public in the Athenex Territory.", "samples": [{"hash": "iM1ih9OIkM9", "uri": "/contracts/iM1ih9OIkM9#product-launch", "label": "Manufacture and Supply Agreement (Athenex, Inc.)", "score": 30.1622180939, "published": true}, {"hash": "8IpA5iX2lmo", "uri": "/contracts/8IpA5iX2lmo#product-launch", "label": "Co Marketing, Manufacture and Supply Agreement (Athenex, Inc.)", "score": 30.1622180939, "published": true}], "size": 2, "hash": "7895c0fd69e1f3142908a49bb4964f5f", "id": 10}, {"snippet_links": [{"key": "to-the-extent", "type": "clause", "offset": [4, 17]}, {"key": "applicable-regulatory-approvals", "type": "definition", "offset": [122, 153]}, {"key": "the-non", "type": "clause", "offset": [158, 165]}, {"key": "fixed-dose-combination-product", "type": "definition", "offset": [166, 196]}, {"key": "information-on", "type": "clause", "offset": [246, 260]}, {"key": "omitted-and-filed-separately-with-the-commission", "type": "clause", "offset": [280, 328]}, {"key": "confidential-treatment", "type": "definition", "offset": [330, 352]}, {"key": "with-respect-to", "type": "clause", "offset": [372, 387]}, {"key": "licensee-shall", "type": "clause", "offset": [444, 458]}, {"key": "licensee-will", "type": "clause", "offset": [482, 495]}, {"key": "in-writing", "type": "definition", "offset": [509, 519]}, {"key": "within-thirty", "type": "clause", "offset": [520, 533]}, {"key": "business-days-of", "type": "clause", "offset": [539, 555]}, {"key": "in-connection-with", "type": "clause", "offset": [687, 705]}, {"key": "notwithstanding-section", "type": "clause", "offset": [798, 821]}, {"key": "in-the-united-states", "type": "clause", "offset": [922, 942]}, {"key": "outside-of-the-united-states", "type": "clause", "offset": [1027, 1055]}, {"key": "in-good-faith", "type": "definition", "offset": [1112, 1125]}], "snippet": "(a) To the extent that Licensee has not launched the Commercialization Product in a given country as of the date that all applicable Regulatory Approvals for the Non-Fixed Dose Combination Product in such country (or other regulatory *** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. jurisdiction) have been obtained, Licensee shall [***]; provided, that, Licensee will notify Lilly in writing within thirty (30) Business Days of all applicable Regulatory Approvals for the Non-Fixed Dose Combination Product being received with respect to such a country [***] in connection with the Commercialization of the Non-Fixed Dose Combination Product in such country. [***].\n(b) Notwithstanding Section 5.2.3(a), by no later than the date upon which Licensee files for Regulatory Approvals of a Product in the United States, Licensee will notify Lilly of where Licensee intends to pursue Regulatory Approval outside of the United States for such Product and will discuss such plans with Lilly in good faith.", "samples": [{"hash": "lJpU4q1qtRR", "uri": "/contracts/lJpU4q1qtRR#product-launch", "label": "License, Development and Commercialization Agreement (Ignyta, Inc.)", "score": 27.2806301117, "published": true}, {"hash": "cyDoXoJMVaE", "uri": "/contracts/cyDoXoJMVaE#product-launch", "label": "License, Development and Commercialization Agreement (Ignyta, Inc.)", "score": 26.9739894867, "published": true}], "size": 2, "hash": "991c07b1cb60ed22cd89f173facaa156", "id": 7}, {"snippet_links": [{"key": "the-product", "type": "clause", "offset": [21, 32]}, {"key": "following-the-effective-date", "type": "clause", "offset": [40, 68]}, {"key": "finished-product", "type": "definition", "offset": [195, 211]}, {"key": "reasonable-control", "type": "clause", "offset": [262, 280]}, {"key": "governmental-authorities", "type": "clause", "offset": [297, 321]}, {"key": "to-issue", "type": "clause", "offset": [329, 337]}, {"key": "marketing-authorization", "type": "definition", "offset": [342, 365]}, {"key": "neither-party-shall", "type": "clause", "offset": [367, 386]}, {"key": "other-party", "type": "definition", "offset": [445, 456]}, {"key": "termination-of-this-agreement-for", "type": "clause", "offset": [484, 517]}, {"key": "the-agreement", "type": "clause", "offset": [532, 545]}, {"key": "full-force-and-effect", "type": "clause", "offset": [562, 583]}, {"key": "in-relation-to", "type": "clause", "offset": [584, 598]}, {"key": "other-product", "type": "clause", "offset": [603, 616]}, {"key": "product-provided", "type": "clause", "offset": [629, 645]}], "snippet": "7.1 EMS shall launch the Product within following the Effective Date. The first actual sale shall be communicated to SONOMA by EMS within 15 (fifteen) days.\n7.2 Should the launch of a Product or Finished Product not be feasible for reasons beyond either Party\u2019s reasonable control (e.g. competent Governmental Authorities refuse to issue the Marketing Authorization) neither Party shall be entitled to claim any damages or compensation from the other Party as a result of the partial termination of this Agreement for such Product. The Agreement shall remain in full force and effect in relation to any other Product or Finished Product provided herein and to which this Agreement were not partially terminated.", "samples": [{"hash": "4nUgQDymlMp", "uri": "/contracts/4nUgQDymlMp#product-launch", "label": "Exclusive License and Distribution Agreement", "score": 31.3408622742, "published": true}, {"hash": "58ov7NhAUYl", "uri": "/contracts/58ov7NhAUYl#product-launch", "label": "Exclusive License and Distribution Agreement (Sonoma Pharmaceuticals, Inc.)", "score": 29.4243659973, "published": true}], "size": 2, "hash": "0215cfe7c2156c90a5b4358ec8d36f51", "id": 6}, {"snippet_links": [{"key": "licensee-shall", "type": "clause", "offset": [0, 14]}, {"key": "commercially-reasonable-efforts", "type": "clause", "offset": [28, 59]}, {"key": "the-product", "type": "clause", "offset": [70, 81]}, {"key": "regulatory-approval", "type": "clause", "offset": [120, 139]}, {"key": "if-required", "type": "definition", "offset": [145, 156]}, {"key": "in-the-licensee-territory", "type": "clause", "offset": [211, 236]}, {"key": "independent-development-activities", "type": "clause", "offset": [319, 353]}, {"key": "approvals-necessary", "type": "clause", "offset": [433, 452]}, {"key": "receipt-of", "type": "clause", "offset": [518, 528]}, {"key": "approval-of", "type": "definition", "offset": [533, 544]}, {"key": "without-limiting-the-generality-of-the-foregoing", "type": "clause", "offset": [572, 620]}, {"key": "after-receiving", "type": "clause", "offset": [759, 774]}, {"key": "where-required-by-applicable-law", "type": "clause", "offset": [800, 832]}, {"key": "applicable-regulatory-authority", "type": "definition", "offset": [941, 972]}, {"key": "ongoing-support", "type": "definition", "offset": [1064, 1079]}], "snippet": "Licensee shall use \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 Commercially Reasonable Efforts to launch the Product for each Indication that has received Regulatory Approval and, if required by Applicable Law, Pricing and Reimbursement Approval in the Licensee Territory (including any Indication that received Regulatory Approval as a result of Ovid\u2019s Independent Development Activities). As applicable, Licensee shall obtain all necessary Pricing and Reimbursement Approvals necessary to list and to launch such Product for such Indication following receipt of MAA Approval of such Product in a country. Without limiting the generality of the foregoing, Licensee shall use \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 Commercially Reasonable Efforts to launch the Product in each country in the Licensee Territory within [***] after receiving Regulatory Approval, or, where required by Applicable Law, after the publication of the Pricing and Reimbursement Approval, of the Product for an Indication from the applicable Regulatory Authority in such country. Thereafter, Licensee shall utilize Commercially Reasonable Efforts in the ongoing support for such Product in such country.", "samples": [{"hash": "lWxaRbPCUI8", "uri": "/contracts/lWxaRbPCUI8#product-launch", "label": "Collaboration and License Agreement (Ovid Therapeutics Inc.)", "score": 32.2005462646, "published": true}, {"hash": "4nOZIQViw3v", "uri": "/contracts/4nOZIQViw3v#product-launch", "label": "Collaboration and License Agreement (Ovid Therapeutics Inc.)", "score": 31.8665294647, "published": true}], "size": 2, "hash": "fc24d474aff294086c14ac6e85e3ed5b", "id": 8}, {"snippet_links": [{"key": "without-limiting", "type": "clause", "offset": [0, 16]}, {"key": "general-obligations", "type": "clause", "offset": [21, 40]}, {"key": "section-41", "type": "clause", "offset": [47, 58]}, {"key": "efforts-to-obtain", "type": "clause", "offset": [111, 128]}, {"key": "pricing-approvals", "type": "clause", "offset": [167, 184]}, {"key": "marketing-materials", "type": "clause", "offset": [216, 235]}, {"key": "major-country", "type": "definition", "offset": [283, 296]}, {"key": "governmental-approval", "type": "clause", "offset": [331, 352]}, {"key": "notwithstanding-the-foregoing", "type": "clause", "offset": [457, 486]}], "snippet": "Without limiting its general obligations under Section 4.1, GENAISSANCE will exert its COMMERCIALLY REASONABLE EFFORTS to obtain, as rapidly as possible, all required pricing approvals and approvals of labelling and marketing materials for a PRODUCT and THERANOSTIC PRODUCTS in each MAJOR COUNTRY and each other country in which a GOVERNMENTAL APPROVAL for such PRODUCT and THERANOSTIC PRODUCTS has been granted, and to launch such PRODUCT in such country. Notwithstanding the foregoing, MERCK KGAA acknowledges that it may not be commercially reasonable for GENAISSANCE to seek pricing approvals or launch a PRODUCT or THERANOSTIC PRODUCT in every country.", "samples": [{"hash": "bo7VjlY2hec", "uri": "/contracts/bo7VjlY2hec#product-launch", "label": "License, Development and Cooperation Agreement (Forest Laboratories Inc)", "score": 21.8535251617, "published": true}, {"hash": "h8EQDHqiqgr", "uri": "/contracts/h8EQDHqiqgr#product-launch", "label": "License, Development and Cooperation Agreement (Genaissance Pharmaceuticals Inc)", "score": 21.0, "published": true}], "size": 2, "hash": "987492ac90db616726049a8204766e02", "id": 9}], "next_curs": "ClcSUWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjMLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2Ihdwcm9kdWN0LWxhdW5jaCMwMDAwMDAwYQyiAQJlbhgAIAA=", "clause": {"children": [["timing-of-launch", "Timing of Launch"], ["decisions-not-to-launch", "Decisions Not to Launch"], ["general", "General"], ["", ""], ["compensation", "Compensation"]], "title": "Product Launch", "parents": [["commercialization", "Commercialization"], ["definitions", "DEFINITIONS"], ["diligence-and-capabilities-plans-and-reporting", "Diligence and Capabilities Plans and Reporting"], ["diligence", "Diligence"], ["development-activities-and-patent-litigation", "Development Activities and Patent Litigation"]], "size": 73, "id": "product-launch", "related": [["product-labeling", "Product Labeling", "Product Labeling"], ["licensed-product", "Licensed Product", "Licensed Product"], ["product", "Product", "Product"], ["product-recall", "Product Recall", "Product Recall"], ["product-recalls", "Product Recalls", "Product Recalls"]], "related_snippets": [], "updated": "2026-05-03T04:25:58+00:00"}, "json": true, "cursor": ""}}